NBIX Form 4 reports multiple insider transactions
Lippoldt Darin reported multiple insider transaction types in a Form 4 filing for NBIX.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Lippoldt Darin reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 71,708 shares at a weighted average price of $124.00 per share. Following the reported transactions, holdings were 4,036 shares.
Insider Trade Summary
5,892 shares exercised/converted
Exercise
14 txns
Insider
Lippoldt Darin
Role
Chief Legal Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 2,017 | $0.00 | $0.00 |
| Exercise | Restricted Stock Unit | 2,083 | $0.00 | $0.00 |
| Grant/Award | Stock Option | 34,909 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Unit | 6,124 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,017 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 1,089 | $124.12 | $135K |
| Exercise | Common Stock | 2,083 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 1,124 | $124.12 | $140K |
| Grant/Award | Common Stock | 9,968 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 5,378 | $124.12 | $668K |
| Gift | Common Stock | 365 | $0.00 | $0.00 |
| Exercise | Restricted Stock Unit | 1,792 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,792 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 967 | $123.10 | $119K |
Holdings After Transaction:
Restricted Stock Unit — 17,620 contracts (Direct);
Stock Option — 34,909 contracts (Direct);
Common Stock — 54,729 shares (Direct)
Footnotes (9)
- F1. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.
- F2. On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award.
- F3. Represents gift/charitable contributions effective February 13, 2026. This is not a market transaction; thus no price has been reported. No value was received for the gifted shares.
- F4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- F5. This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,792 shares on February 12, 2026, and will vest as to 1,792 shares on February 12, 2027, 1,792 shares on February 12, 2028, and 1,792 shares on February 12, 2029, subject to the terms and conditions of the award.
- F6. This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,017 shares on February 13, 2025, vested as to 2,017 shares on February 13, 2026, and will vest as to 2,018 shares on February 13, 2027, and 2,018 shares on February 13, 2028, subject to the terms and conditions of the award.
- F7. This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025, vested as to 2,083 shares on February 13, 2026, and will vest as to 2,083 shares on February 13, 2027, subject to the terms and conditions of the award.
- F8. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- F9. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Neurocrine Biosciences (NBIX) disclose in Darin Lippoldt’s latest Form 4?
The filing shows Chief Legal Officer Darin Lippoldt had restricted stock units vest and convert into Neurocrine common shares, received new stock option and RSU grants, had shares withheld to cover taxes, and made a small share gift, with no open‑market sales reported.
What new equity awards did NBIX’s Chief Legal Officer receive in this Form 4?
On February 13, 2026, Darin Lippoldt received a stock option covering 34,909 Neurocrine shares at a $124.12 exercise price and 6,124 new restricted stock units. The option vests monthly over 48 months, while the RSUs vest annually over four years starting in 2027.
What happened with the performance RSUs reported in the NBIX Form 4?
Performance RSUs granted on May 19, 2023 vested on February 13, 2026 after performance over a three‑year period was certified. The payout was 125% of the target, resulting in 9,968 Neurocrine common shares being issued to Darin Lippoldt at no cost.
How will the newly granted Neurocrine RSUs to Darin Lippoldt vest over time?
The newly granted 6,124 restricted stock units will vest in four equal annual installments. One‑quarter of the units will vest on each of February 13, 2027, 2028, 2029, and 2030, assuming continued satisfaction of the award’s terms and conditions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates